Comparative Pharmacology
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 9.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLEBRINE versus OMNIPAQUE 9.
CHOLEBRINE vs OMNIPAQUE 9
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cholebrine is an iodinated contrast agent that attenuates X-rays, improving visualization of anatomical structures during imaging procedures.
Iodinated nonionic contrast agent that attenuates X-rays, enhancing vascular and tissue contrast. Its iodine content (350 mg/mL) provides radiopacity, while low osmolality reduces adverse hemodynamic effects.
1-2 mCi (37-74 MBq) intravenously as a single dose for hepatobiliary scintigraphy.
Omnipaque 9 (iohexol 9 mg I/mL) is administered intravenously. For CT enhancement, typical adult dose is 50-100 mL (450-900 mg I) by slow IV injection.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours in adults with normal renal function; prolonged to 6-12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 1–2 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Primarily renal excretion as unchanged drug (70-80%) and glucuronide conjugates (15-20%); biliary/fecal elimination accounts for <5%.
Renal: >95% unchanged via glomerular filtration; fecal: <1%.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent